GCIA
CRXTW

Gabelli & Co Investment Advisers’s Clarus Therapeutics Holdings, Inc. Warrants CRXTW Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio CRXTW Stock Details CRXTW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-23,487
Closed -$18K – 541
2021
Q2 		$18K Buy
+23,487
New +$14.7K ﹤0.01% 436

Other funds holding CRXTW

LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Gabelli & Co Investment Advisers's CRXTW Position: Q3 2021 in Review

Gabelli & Co Investment Advisers sold out of Clarus Therapeutics Holdings, Inc. Warrants (CRXTW) in Q3 2021, closing a stake of 23,487 shares — an estimated $18K sold.

Gabelli & Co Investment Advisers first reported a position in CRXTW in Q2 2021 and held it in 1 quarter. The position peaked at $18K in Q2 2021. 22 funds tracked by Wall St. Rank hold CRXTW as of Q3 2021.

  • Gabelli & Co Investment Advisers reported no remaining Clarus Therapeutics Holdings, Inc. Warrants position as of Q3 2021 after selling out during the quarter.
  • Gabelli & Co Investment Advisers sold 23,487 Clarus Therapeutics Holdings, Inc. Warrants shares in Q3 2021, an estimated $18K.
  • Gabelli & Co Investment Advisers first reported a position in Clarus Therapeutics Holdings, Inc. Warrants in Q2 2021 and held it in 1 quarter.
  • Gabelli & Co Investment Advisers's Clarus Therapeutics Holdings, Inc. Warrants position peaked at $18K in Q2 2021.
  • 22 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Warrants as of Q3 2021.

Based on Gabelli & Co Investment Advisers's 13F filing for Q3 2021, filed 12 Nov 2021.